Navigation Links
Rudy Mazzocchi Joins the Greatbatch Board of Directors as he Continues to Expand his Presence in the Med-tech Industry
Date:1/22/2013

of ELENZA, Inc.; a venture-backed ophthalmic device company that is developing the world’s first electro-active AutoFocal Intraocular Lens for patients affected by cataracts. This proprietary technology is intended to offer the patient an implantable lens that replaces the aging “cloudy” natural lens with a programmable, autofocusing acrylic lens that contains its own rechargeable power source, biosensors and programmable microchips. ELENZA is completing its Swiss-based development efforts and transitioning into a production phase in order to initiate clinical studies for European commercial approval in 2014-2015.

When asked “what’s next?”, his audience needs to retake their seat. Mazzocchi will tell-a-tale of how the expansive platform of his ELENZA technology has enormous applications not only inside the eye, but for other active implants throughout the body. He’ll then jump to a story about another patented idea that is being developed in collaboration at the Florida Institute of Technology (Melbourne, FL); one that was designed to help repair the damaged eyes of his younger brother and thousands of others suffering from the same clinical problem. Mazzocchi will then end with an animated description of his next novel, EQUITY of FEAR, anticipated for release in February of 2013.

Mazzocchi’s BIO:

Rudy is best known as a medical device and biotechnology entrepreneur, inventor, and angel investor, with a history of starting new te
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rudy Mazzocchi Prepares to Release the Second Thriller in The EQUITY Series Trilogy, entitled EQUITY of FEAR
2. Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
3. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
4. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
5. John A. Orwin Joins Array BioPharma Board Of Directors
6. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
7. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
8. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
9. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
10. New Physician Joins Dallas Based Fertility Center
11. Maxx Performance Joins GreenPalm to Promote Sustainable Harvest of Palm Oil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis ... from 2015 to 2020. The bioscience market is expected to grow at the highest ... of failure analysis equipment in the research labs and academic institutions for root cause ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/3/2015)... , July 3, 2015 ... 22. september 2015 på  http://www.openinnovationinscience.at om ... der finder sted i Wien ... undersøgelse af internationale forskere og videnskabsmænd foretaget ... to største udfordringer for sundhedsvidenskaben manglen på ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: